Stephanie Lembke
YOU?
Author Swipe
View article: Discordance between patient and physician reported global disease activity in PsA is associated with mental health—a cross-sectional analysis
Discordance between patient and physician reported global disease activity in PsA is associated with mental health—a cross-sectional analysis Open
Psoriatic arthritis (PsA) is a complex disease with heterogeneous disease manifestations. Composite scores including patient reported parameters are the recommended tools to measure these different aspects. Patient and physician often show…
View article: OA17 Factors associated with biologics treatment response at 1 year amongst patients with psoriatic arthritis - results from the British Society of Rheumatology Psoriatic Arthritis Register (BSR-PsA)
OA17 Factors associated with biologics treatment response at 1 year amongst patients with psoriatic arthritis - results from the British Society of Rheumatology Psoriatic Arthritis Register (BSR-PsA) Open
Background/Aims Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) can significantly improve outcomes in psoriatic arthritis (PsA), but not all patients respond. Our aim was to characterise patients most lik…
View article: The worldwide prevalence of psoriatic arthritis—a systematic review and meta-analysis
The worldwide prevalence of psoriatic arthritis—a systematic review and meta-analysis Open
Objectives Previous attempts to pool prevalence studies in PsA have failed to take account of important methodological differences between studies that may have created biased estimates. The aim of this review is to estimate the prevalence…
View article: P183 Disease activity, comorbidities and functional status predict treatment response to biologic and targeted synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis
P183 Disease activity, comorbidities and functional status predict treatment response to biologic and targeted synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis Open
Background/Aims Much discussion surrounds the optimal therapeutic treatment plan for biologic and targeted synthetic disease modifying anti-rheumatic drugs (bDMARDs/tsDMARDs) when treating psoriatic arthritis (PsA). The current study aims …